These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 8773955)
1. Application of computer-assisted radiotelemetry in the pharmacokinetic and pharmacodynamic modeling of procainamide and N-acetylprocainamide. Kharidia J; Eddington ND J Pharm Sci; 1996 Jun; 85(6):595-9. PubMed ID: 8773955 [TBL] [Abstract][Full Text] [Related]
2. [Combined pharmacokinetic and pharmacodynamic model analysis for procainamide and its metabolite]. Liu XQ; Huang SK Zhongguo Yao Li Xue Bao; 1991 Jan; 12(1):7-11. PubMed ID: 1719744 [TBL] [Abstract][Full Text] [Related]
3. The influence of selected general anesthetics on pharmacokinetic parameters of some antiarrhythmic drugs in rabbits. Part I. Procainamide and its active metabolite-N-acetylprocainamide. Orszulak-Michalak D Acta Pol Pharm; 1995; 52(2):141-6. PubMed ID: 8960244 [TBL] [Abstract][Full Text] [Related]
4. Trimethoprim inhibition of the renal clearance of procainamide and N-acetylprocainamide. Vlasses PH; Kosoglou T; Chase SL; Greenspon AJ; Lottes S; Andress E; Ferguson RK; Rocci ML Arch Intern Med; 1989 Jun; 149(6):1350-3. PubMed ID: 2471472 [TBL] [Abstract][Full Text] [Related]
6. The influence of moderate and chronic exercise training on the pharmacokinetics of procainamide and N-acetylprocainamide. Eddington ND; Adekoya F; Kharidia J Biopharm Drug Dispos; 1998 Jul; 19(5):291-6. PubMed ID: 9673780 [TBL] [Abstract][Full Text] [Related]
7. Comparison of the pharmacokinetic and pharmacodynamic properties of procainamide and N-acetylprocainamide. Atkinson AJ; Ruo TI; Piergies AA Angiology; 1988 Jul; 39(7 Pt 2):655-67. PubMed ID: 2457345 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic modeling and simulation of procainamide and N-acetylprocainamide in a patient receiving continuous renal replacement therapy: a novel approach to guide renal dose adjustments. Mohamed AN; Abdelhady AM; Spencer D; Sowinski KM; Tisdale JE; Overholser BR Am J Kidney Dis; 2013 Jun; 61(6):1046-8. PubMed ID: 23562328 [TBL] [Abstract][Full Text] [Related]
9. [Combined pharmacokinetic-pharmacodynamic model of procainamide in rabbits with induced ventricular fibrillation threshold (VFT) changes]. Lu H; Huang SK; Yang JY; Lu DY; Lu JF Yao Xue Xue Bao; 1991; 26(7):481-7. PubMed ID: 1725230 [TBL] [Abstract][Full Text] [Related]
10. [Verification of therapeutic levels of procainamide and N-acetyl- procainamide in ventricular arrhythmia]. Sinkiewicz W; Marzec A; Jankowski A; Hoffmann A; Makuch K; RomaĆski B Pol Tyg Lek; 1990 Jun 4-11; 45(23-24):458-60. PubMed ID: 1703654 [TBL] [Abstract][Full Text] [Related]
11. Comparison of antiarrhythmic effects of procainamide, N-acetylprocainamide, and p-hydroxy-N-(3-diethylaminopropyl)benzamide. Reynolds RD; Burmeister WE; Calzadilla SV; Lee RJ; Reidenberg MM; Drayer DE Proc Soc Exp Biol Med; 1982 Feb; 169(2):156-60. PubMed ID: 6174988 [No Abstract] [Full Text] [Related]
12. Trimethoprim alters the disposition of procainamide and N-acetylprocainamide. Kosoglou T; Rocci ML; Vlasses PH Clin Pharmacol Ther; 1988 Oct; 44(4):467-77. PubMed ID: 2458879 [TBL] [Abstract][Full Text] [Related]
13. Effects of desethylamiodarone on the electrocardiogram in conscious freely moving animals: pharmacokinetic and pharmacodynamic modeling using computer-assisted radio telemetry. Kharidia J; Eddington ND Biopharm Drug Dispos; 1996 Mar; 17(2):93-106. PubMed ID: 8907716 [TBL] [Abstract][Full Text] [Related]
14. Class I antiarrhythmic agents: quinidine, procainamide and N-acetylprocainamide, disopyramide. Roden DM; Woosley RL Pharmacol Ther; 1983; 23(2):179-91. PubMed ID: 6199801 [No Abstract] [Full Text] [Related]
15. Acecainide (N-acetylprocainamide). A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cardiac arrhythmias. Harron DW; Brogden RN Drugs; 1990 May; 39(5):720-40. PubMed ID: 1693889 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of N-acetylation of procainamide and renal clearance of N-acetylprocainamide by para-aminobenzoic acid in humans. Tisdale JE; Rudis MI; Padhi ID; Svensson CK; Webb CR; Borzak S; Ware JA; Krepostman A; Zarowitz BJ J Clin Pharmacol; 1995 Sep; 35(9):902-10. PubMed ID: 8786250 [TBL] [Abstract][Full Text] [Related]
17. Clinical pharmacokinetics of N-acetylprocainamide. Connolly SJ; Kates RE Clin Pharmacokinet; 1982; 7(3):206-20. PubMed ID: 6178545 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic and pharmacodynamic comparisons of twice daily and four times daily formulations of procainamide in patients with frequent ventricular premature depolarization. Yang BB; Abel RB; Uprichard AC; Smithers JA; Forgue ST J Clin Pharmacol; 1996 Jul; 36(7):623-33. PubMed ID: 8844445 [TBL] [Abstract][Full Text] [Related]
19. The pharmacokinetics and pharmacodynamics of procainamide in horses after intravenous administration. Ellis EJ; Ravis WR; Malloy M; Duran SH; Smyth BG J Vet Pharmacol Ther; 1994 Aug; 17(4):265-70. PubMed ID: 7525982 [TBL] [Abstract][Full Text] [Related]
20. [A new anti-arrhythmia drug. II. Comparative studies of the effects of a new acyl derivative of procainamide, procainamide and N-acetylprocainamide on blood pressure and the electrocardiogram in rabbits]. Kusowska J Acta Pol Pharm; 1989; 46(1):90-7. PubMed ID: 2479226 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]